Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Danilo PerrottiAnupriya AgarwalClaire M LucasGoutham NarlaPaolo NevianiMaria-Dolores OderoPeter P RuvoloNicole M VerrillsPublished in: Science translational medicine (2020)
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.